2011
DOI: 10.1016/j.jinorgbio.2011.03.003
|View full text |Cite
|
Sign up to set email alerts
|

Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
36
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 75 publications
(37 citation statements)
references
References 34 publications
1
36
0
Order By: Relevance
“…As well-known chelating collector, hydroxamic acids are effective ligands with metal ions. The chelating performance of hydroxamic acids with transition metals including Fe, Ni, Cu and Zn has been studied through theoretical and experimental methods [4][5][6]. Research of chelation between hydroxamic acids and Pb has also been reported [7].…”
Section: Introductionmentioning
confidence: 99%
“…As well-known chelating collector, hydroxamic acids are effective ligands with metal ions. The chelating performance of hydroxamic acids with transition metals including Fe, Ni, Cu and Zn has been studied through theoretical and experimental methods [4][5][6]. Research of chelation between hydroxamic acids and Pb has also been reported [7].…”
Section: Introductionmentioning
confidence: 99%
“…However, hydroxamic acids possess stronger abilities for selectively chelating metal ions [1][2][3][4][5][6][7]. Commonly, the two O atoms in carbonyl and hydroxyl groups of a hydroxamate molecule bond with metal cation to form a five-membered ring structure.…”
Section: Introductionmentioning
confidence: 99%
“…5 It is well established that metal-chelating motifs bind tightly to the Zn(II) ion in the active site of HDAC enzymes and can lead to reversible inhibition of their biological function. 6 HDAC inhibitors (HDACi) have great potential as therapeutic agents, with several advancing into clinical trials; and multiple panactive HDACi are FDA approved for T-cell lymphoma and multiple myeloma.…”
mentioning
confidence: 99%